InsidersTradesSigma
Total declarations
Company
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
7
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Mickle Travis C, Chairman & CEO. Director active across 1 company, notably Kempharm, INC. Cumulatively, 9 filings have been recorded. Breakdown: 7 buys · 0 sell. Total volume traded: €152k. Activity tracked since 14 June 2021. The latest transaction was filed on 25 May 2022 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations9 total
2,000 shares@ US$4.35555.4% of flowCommon StockSEC:0001437749-22-013570:0
Ideal exit: 19 Feb 2023 (T+270)
2,250 shares@ US$8.229510.7% of flowCommon StockSEC:0001437749-21-027301:0
Ideal exit: 15 Aug 2022 (T+270)
2,250 shares@ US$8.229510.7% of flowCommon StockSEC:0001437749-21-027301
Ideal exit: 15 Aug 2022 (T+270)
5,000 shares@ US$8.921524.8% of flowCommon StockSEC:0001437749-21-021199:0
Ideal exit: 27 May 2022 (T+270)
5,000 shares@ US$8.921524.8% of flowCommon StockSEC:0001437749-21-021199
Ideal exit: 27 May 2022 (T+270)
96,153 shares0Common StockSEC:0001437749-21-020865:0
96,153 shares0Common StockSEC:0001437749-21-020865
1,500 shares@ US$14.4311.7% of flowCommon StockSEC:0001437749-21-014735
Ideal exit: 11 Mar 2022 (T+270)
1,500 shares@ US$14.4311.7% of flowCommon StockSEC:0001437749-21-014735:0
Ideal exit: 11 Mar 2022 (T+270)
9 of 9 declarations
About Mickle Travis C
Travis C. Mickle is the President and Chief Executive Officer of KEMPHARM, INC. He is responsible for the strategic and operational leadership of the company. Mickle plays a key role in innovation and product development, thereby contributing to KEMPHARM's growth.
